Companies CytoDyn Inc.
CytoDyn (CYDY): executive pay, fiscal 2026
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me CytoDyn Inc.’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $783,850FY2025
- $1,833,398FY2026
CEO total pay was $1,833,398 in fiscal 2026, up from $783,850 in fiscal 2025.
FY2026: salary $409,896 · bonus $200,000 · stock awards $0 · option awards $1,208,184
Frequently asked questions
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Robert Hoffman | $450,000 | $225,000 | $0 | $1,208,184 | $0 | $0 | $16,425 | $1,899,609 |
| Chief Financial Officer | ||||||||
| Jacob Lalezari | 409,896 | 200,000 | 0 | 1,208,184 | 0 | 0 | 15,318 | 1,833,398 |
| Chief Executive Officer | ||||||||
| Tyler Blok | 370,324 | 200,000 | 0 | 805,456 | 0 | 0 | 15,519 | 1,391,299 |
| Chief Legal Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2026 total | FY2025 total | FY2024 total | Δ FY2025→2026 |
|---|---|---|---|---|
| Robert Hoffman | $1,899,609 | $388,526 | — | ↑ +1,511,083 |
| Jacob Lalezari | 1,833,398 | 783,850 | — | ↑ +1,049,548 |
| Tyler Blok | 1,391,299 | 532,494 | — | ↑ +858,805 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The Company believes its executive compensation program should be designed to attract, motivate, and retain highly qualified executives by paying them competitively and rewarding and encouraging individual and superior company performance, on both a short- and long-term basis, thereby aligning our executives’ behavior with long-term stockholder interests.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | false |
Equity grants and outstanding awards
No plan-based awards are on file for this fiscal year.
Outstanding equity awards at fiscal year-end 2026
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Tyler Blok | Option | 4,168 | 0.21 | — |
| Tyler Blok | Option | 250,008 | 0.21 | — |
| Tyler Blok | Option | 625,008 | 0.13 | — |
| Robert Hoffman | Option | 729,167 | 0.41 | — |
| Jacob Lalezari | Option | 1,375,000 | 0.21 | — |
| Jacob Lalezari | Option | 1,500,000 | 0.13 | — |
| Tyler Blok | Option | 3,249,794 | 0.28 | — |
| Robert Hoffman | PSU | 3,500,000 | — | 1,050,000 |
| Jacob Lalezari | Option | 4,874,691 | 0.28 | — |
| Robert Hoffman | Option | 4,874,691 | 0.28 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Tanya D. UrbachIndependent · Board Chair · Audit · Compensation · Nom/Gov (Chair) | $98,498 | — | $129,382 | — | — | $227,880 |
| Stephen M. SimesIndependent · Audit · Compensation (Chair) | 65,000 | — | 129,382 | — | — | 194,382 |
| Ryan M. DunlapIndependent · Audit (Chair) · Nom/Gov | 65,000 | — | 129,382 | — | — | 194,382 |
| Karen J. Brunke, Ph.DIndependent · Compensation | 47,500 | — | 129,382 | — | — | 176,882 |
| Lishomwa C. Ndhlovu, M.D., Ph.DIndependent · Nominating and Corporate Governance | 45,000 | — | 129,382 | — | — | 174,382 |
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | $129,382 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2026 |
|---|---|
| Cash retainers and fees | $320,998 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $320,998 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names CytoDyn as a peer
Companies that benchmark against CYDY
No companies currently name CYDY as a compensation peer in their most recent disclosure.
This is the complete answer, not a partial one — the list is never padded.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | CytoDyn Inc. | 2026 | Jacob Lalezari | $409,896 | $0 | $1,208,184 | $0 | $1,833,398 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
No say-on-pay vote is on file for this company.
Insider trades since the proxy
No insider equity transactions reported since the proxy statement.
Sources (11 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Robert Hoffman. DEF 14A, filed 2026-09-28. Section “Executive Compensation”. As printed: 1,899,609. View filing ↗
- Section 01, Jacob Lalezari. DEF 14A, filed 2026-09-28. Section “Executive Compensation”. As printed: 1,833,398. View filing ↗
- Section 01, Tyler Blok. DEF 14A, filed 2026-09-28. Section “Executive Compensation”. As printed: 1,391,299. View filing ↗
- Section 08, Tanya D. Urbach. DEF 14A, filed 2026-09-28. Section “Director Compensation”. As printed: 227,880. View filing ↗
- Section 08, Stephen M. Simes. DEF 14A, filed 2026-09-28. Section “Director Compensation”. As printed: 194,382. View filing ↗
- Section 08, Ryan M. Dunlap. DEF 14A, filed 2026-09-28. Section “Director Compensation”. As printed: 194,382. View filing ↗
- Section 08, Karen J. Brunke, Ph.D. DEF 14A, filed 2026-09-28. Section “Director Compensation”. As printed: 176,882. View filing ↗
- Section 08, Lishomwa C. Ndhlovu, M.D., Ph.D. DEF 14A, filed 2026-09-28. Section “Director Compensation”. As printed: 174,382. View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 09b board cost (computed). Computed. Cash 320,998 + equity 0 + all other 0 = 320,998, summed across the director compensation table rows.
- CytoDyn Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-09-28. CEO total compensation as printed in CytoDyn Inc.'s own proxy. As printed: 1,833,398. View filing ↗